Kansas City, Kansas Clinical Trials

A listing of Kansas City, Kansas clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1003 clinical trials
featured
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis is a type of bone marrow cancer that usually develops slowly and disrupts body's normal production of blood cells. It causes bone marrow scarring, leading to severe anemia that can cause weakness and fatigue. It can also cause a low number of blood-clotting cells called platelets, which increases …

University of Kansas Cancer Center /ID# 218144
 (6.3 away) Contact site
  • 32 views
  • 29 Apr, 2021
  • +148 other locations
featured
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

www.MyelofibrosisResearch.com This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.

MidAmerica Division, Inc. /ID# 222058
 (9.3 away) Contact site
  • 251 views
  • 29 Apr, 2021
  • +134 other locations
featured
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension

The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time of consent. Prior to randomization, subjects will be hypertensive in the absence of hypertension medication.

renal angiogram
hypertension
antihypertensive drugs
angiography
antihypertensive therapy
Saint Luke's Hospital
 (4.4 away) Contact site
  • 877 views
  • 13 Jun, 2021
  • +82 other locations
featured
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.  

metastatic cancer
FGFR2
primary cancer
cancer
The University of Kansas Cancer Center
 (6.1 away) Contact site
  • 154 views
  • 14 Dec, 2020
  • +154 other locations
featured
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)  

bendamustine
measurable disease
rituximab
refractory follicular lymphoma
obinutuzumab
University of Kansas Cancer Center
 (6.1 away) Contact site
  • 560 views
  • 23 Nov, 2020
  • +11 other locations
featured
ECOSPOR III: A Phase 3 Multicenter, RandomizeEd, Double Blind, Placebo COntrolled, Parallel Group Study to Evaluate the Safety, Tolerability, & Efficacy of SER-109 vs. Placebo to Reduce Recurrence of ClOstRidium Difficile Infection (CDI) in Adults

ECOSPOR III is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the safety, tolerability, and efficacy of SER-109 versus placebo in adult subjects 18 years of age or older with recurrent CDI, defined as: a history of ≥ 3 CDI episodes within 9 months, inclusive of the current …

vancomycin
clostridium difficile
antibiotics
antibiotic therapy
fidaxomicin
University of Kansas Medical Center
 (6.6 away) Contact site
  • 1092 views
  • 21 Dec, 2020
  • +71 other locations
featured
ECOSPOR IV: An Open-Label Extension of Study SERES-012 and Open-Label Program for Evaluating SER-109 in Adult Subjects with Recurrent Clostridioides difficile Infection (RCDI)

ECOSPOR IV is a Phase 3, multicenter, Open Label study to evaluate the safety and tolerability of SER-109 in adult subjects with recurrent CDI.

clostridium difficile
University of Kansas Medical Center
 (6.6 away) Contact site
  • 37 views
  • 21 Dec, 2020
  • +76 other locations
featured
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension

RADIANCE-II is a pivotal trial, currently enrolling patients, to study the safety and effectiveness of the Paradise System to reduce blood pressure in patients with hypertension, in the absence of antihypertensive medications. RADIANCE-II is currently enrolling patients with uncontrolled blood pressure on 0-2 medications.  

Saint Luke's Hospital
 (4.1 away) Contact site
  • 315 views
  • 30 Mar, 2021
  • +20 other locations
featured
Alpha-1 Study: A research study for individuals with Alpha-1 Antitrypsin Deficiency

The Alpha-1 Study is a clinical research study currently enrolling individuals 18 to 78 (inclusive) with Alpha-1 Antitrypsin Deficiency.   The purpose of this study is to evaluate the safety, tolerability, and effectiveness of an investigational medication in individuals with Alpha-1 Antitrypsin Deficiency. Interested individuals will be evaluated during a screening …

alpha 1-antitrypsin
alpha1-proteinase inhibitor (human)
deficiency
Alpha 1 Study Center
 (4.1 away) Contact site
  • 145 views
  • 23 Nov, 2020
  • +6 other locations
featured
Vielight RX Plus for the Treatment of COVID-19 Respiratory Symptoms

We are running a clinical trial designed for virtual and at-home participation, throughout the United States and Ontario, Canada. You can join and participate in the study remotely, without leaving the comfort of your home. The study is testing our investigational light therapy device (photobiomodulation device) to see if we …

Impact Clinical Trials (Remote)
 (2.8 away) Contact site
  • 0 views
  • 19 May, 2021
  • +201 other locations